- DKK547.10m
- DKK499.72m
- DKK40.29m
Brief: Bioporto Q2 EBIT Loss Narrows To DKK 14.5 Mln
Brief: Bioporto Q1 EBIT Loss Widens To DKK 18.2 Mln
Brief: Peter Mørch Eriksen Resigns As CEO Of Bioporto
Brief: Bioporto Starts Search For New CFO As Ole Larsen Resigns
Brief: Bioporto Says Expects To Complete Clinical Study And Submit A De Novo Application To FDA For Pediatric Use Of NGAL Test This Summer
Brief: Bioporto Announces CE Mark Of Near-Patient Test For Kidney Injury
Brief: Bioporto A/S - Q3 EBIT Loss Dkk 17.7 Million
Brief: Bioporto -Completion Of Rights Issue Total Number Of Shares And Voting Rights
Brief: Bioporto Rights Issue Fully Subscribed
Brief: Bioporto Plans Clinical Evaluation Of Test For Rapid Detection Of Covid-19 Virus
Brief: BioPorto Q2 EBIT Loss At DKK 16.6 Mln
Brief: Bioporto: Danish Team Of Researchers To Test Treatment Of Critically Ill Patients Suffering From COVID-19
Brief: Bioporto Q1 EBIT Loss Narrows To DKK 16.4 Mln
Brief: Bioporto Rights Issue Fully Subscribed
Brief: BioPorto And University Of Southern Denmark Are Developing COVID-19 Tests
Directorate Change
Brief: Bioporto Says Revising Subscription Price In Its Intended Rights Issue
Brief: Bioporto - FY EBIT DKK 74 mln
Brief: Bioporto Q3 EBIT Loss Widens To DKK 24 Million